Three-Dimensional Quantitative Validation of Breast MRI Background Parenchymal Enhancement Assessments

Publication date: Available online 8 February 2016
Source:Current Problems in Diagnostic Radiology
Author(s): Richard Ha, Eralda Mema, Xiaotao Guo, Victoria Mango, Elise Desperito, Jason Ha, Ralph Wynn, Binsheng Zhao
IntroductionThe MRI background parenchymal enhancement (BPE) and its clinical significance as a bio-marker of breast cancer risk has been proposed based on qualitative studies. Previous BPE quantification studies lack appropriate correlation with BPE qualitative assessments. The purpose of this study is to validate our three-dimensional (3D) BPE quantification method with standardized BPE qualitative cases.MethodsAn IRB approved study reviewed 500 consecutive MRI cases (from 1/2013-12/2014) using a strict inclusion criteria and 120 cases that best represented each of the BPE qualitative categories (minimal/mild/moderate/marked) were selected. Blinded to the qualitative data, fibroglandular tissue (FGT) contours of pre-and post-contrast images were delineated using an in-house, proprietary segmentation algorithm. Metrics of BPE were calculated including % BPE [(ratio of BPE volume to FGT volume)x100] at multiple threshold levels to determine the optimal cut-off point for BPE quantification that best correlated with the reference BPE qualitative cases.ResultsThe highest positive correlation was present at 1.5x pre-SI threshold level (r=0.84, p <0.001). At this level, the BPE qualitative assessment of minimal, mild, moderate and marked correlated with the mean quantitative % BPE of 14.1%(95%CI, 10.9-17.2), 26.1%(22.8-29.3), 45.9%(40.2-51.7) and 74.0%(68.6-79.5) respectively. A one-way ANOVA with post-hoc analysis showed that at 1.5x pre-SI level, the quantitative % BPE measurements best differentiated the four reference BPE qualitative groups [F(3,117)=106.8, p<0.001].ConclusionOur 3D BPE quantification methodology was validated using the reference BPE qualitative cases and could become an invaluable clinical tool to more accurately assess breast cancer risk and to test chemoprevention strategies.

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://ift.tt/1ScyMTP
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1Xf6XJV
via IFTTT